Literature DB >> 27885682

Fractional laser-assisted drug uptake: Impact of time-related topical application to achieve enhanced delivery.

Christina A Banzhaf1,2, Daniel Thaysen-Petersen1, Christiane Bay1, Peter A Philipsen1, Mette Mogensen1, Tarl Prow2, Merete Haedersdal1.   

Abstract

BACKGROUND AND
OBJECTIVE: Ablative fractional laser (AFXL) is acknowledged to increase uptake of topically applied agents in skin. AFXL channels gradually close over time, which may impair this capability. The time frame for applying a drug after AFXL exposure remains to be established. The aim of this study, was to investigate the importance of time-related topical application after AFXL exposure and to relate resultant uptake in skin with AFXL channel morphology and skin integrity. STUDY DESIGN/
MATERIALS AND METHODS: Buttock skin of healthy volunteers (n = 11) was exposed to 10,600 nm fractional CO2 laser using 5% density, 120 μm beam diameter, 15 mJ pulse energy. Sodium fluorescein (NaF) a small, hydrophilic molecule (370 MW, log P =  -1.52) was applied under standardized conditions at specific time points after laser exposure (0, 2, 5, 10, 30, 60, 90 minute, 6, 24, and 48 hours). Fluorescence photography collected fluorescence images up to 180 minute after NaF application. Optical coherence tomography (OCT) assessed AFXL channel dimensions and transepidermal water loss (TEWL) estimated loss of skin integrity.
RESULTS: Fluorescence intensities (FI) were significantly elevated when NaF was applied up to 6 hours after laser exposure compared to non-laser-processed skin (median FI 1947 arbitrary units [interquartile range 1,246-3,560] versus 1,004 [350-1,538], P < 0.02). The highest FI occurred when NaF was applied within 30 minute after laser exposure and similar FI were reached for applications at 0, 2, 5, 10, and 30 minute after AFXL exposure (0 minute: 3,866 [3,526-4,575], 30 minute: 3,775 AU [3,070-4,484], P > 0.1). NaF application later than 30 minute after AFXL exposure resulted in gradually decreasing FI, becoming similar to intact skin when applied at 24-48 hours after AFXL exposure (P > 0.2). OCT images demonstrated that AFXL channels closed over time (100% [100-100%] open up to 30 minute, 75% [4-86%] at 6 hours and 3% [0-15%] at 24-48 hours after AFXL exposure). TEWL measurements proved loss of skin integrity up to 6 hours after AFXL exposure, while integrity was similar in laser-exposed and non-laser-exposed skin at 24-48 hours.
CONCLUSIONS: The time frame to maintain enhanced drug delivery sustained for several hours after AFXL exposure, corresponding to channel morphology and loss of skin integrity. Lasers Surg. Med. 49:348-354, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  fluorescence intensity; imaging; optical coherence tomography; sodium fluorescein; topical drug delivery

Mesh:

Substances:

Year:  2016        PMID: 27885682     DOI: 10.1002/lsm.22610

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  3 in total

1.  Efficacy and Safety of Using Noninsulated Microneedle Radiofrequency Alone versus in Combination with Polynucleotides for Treatment of Periorbital Wrinkles.

Authors:  Yuri Yogya; Rungsima Wanitphakdeedecha; Supisara Wongdama; Yanisorn Nanchaipruek; Chadakan Yan; Sarawalai Rakchart
Journal:  Dermatol Ther (Heidelb)       Date:  2022-04-30

2.  Hypertrophic Scar Outcomes in Fractional Laser Monotherapy Versus Fractional Laser-Assisted Topical Corticosteroid Delivery: A Randomized Clinical Trial.

Authors:  Woraphong Manuskiatti; Arisa Kaewkes; Chadakan Yan; Janice Natasha Ng; Joshua Zev Glahn; Rungsima Wanitphakdeedecha
Journal:  Acta Derm Venereol       Date:  2021-03-17       Impact factor: 3.875

3.  Fractional laser-assisted topical delivery of bleomycin quantified by LC-MS and visualized by MALDI mass spectrometry imaging.

Authors:  Kristoffer K Hendel; Charlotte Bagger; Uffe H Olesen; Christian Janfelt; Steen H Hansen; Merete Haedersdal; Catharina M Lerche
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.